KCT0004802
Terminated
未知
Effects of dapaglifloziN Therapy on myocardial perfusion Reserve in prediabetic patients with stable coronarY artery disease
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Asan Medical Center
- Enrollment
- 60
- Status
- Terminated
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Men or women at least 18 years of age
- •2\)Prediabetes by ADA criteria (fasting glucose 100\-125mg/dl, or HbA1C 5\.7\-6\.4% )(3\)
- •3\)Stable coronary artery disease
- •4\)Global myocardial perfusion reserve (MPR) index \< 2\.0
- •5\)The patient or guardian agrees to the study protocol and the schedule of clinical and dynamic SPECT follow\-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site.
Exclusion Criteria
- •1\) Contraindications to dapapagliflozin
- •2\) Significant renal disease manifested by creatinine clearance of(eGFR\<30 ml/min/1\.73m2
- •3\) Unstable or rapidly progressing renal disease
- •4\) Acute coronary syndrome, or any other major cardiovascular events within the previous 6 months
- •5\) Stent placement, or coronary artery bypass graft surgery within the previous 6 months
- •6\) Planned revascularization within 6 months
- •7\) Significant disease (diameter stenosis \>70% by coronary CT angiography) in major epicardial coronary arteries
- •8\) Heart failure requiring loop diuretics
- •9\) Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation (ALT or AST \> 3 times upper limit of normal).
- •10\) Contraindication to adenosine stress test\*
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
DTYPE 2 DIABETESMedDRA version: 20.0Level: SOCClassification code 10027433Term: Metabolism and nutrition disordersSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Hormonal diseases [C19]EUCTR2016-003614-27-ITIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI52
Terminated
Phase 4
Effects of dapaglifloziN Therapy on Myocardial Perfusion Reserve in Prediabetic Patients With Stable coronarY Artery DiseaseCoronary Artery DiseasePrediabetic StateNCT04330079CHEOL WHAN LEE, M.D., Ph.D2
Unknown
Phase 3
Effects of SGLT2 Inhibition on Myocardial Insulin SensitivityType2 Diabetes MellitusStable Coronary Artery DiseaseNCT03313752Andrea Giaccari52
Not yet recruiting
Phase 2
Dapagliflozin in Pulmonary Arterial HypertensioPulmonary arterial hypertension.Primary pulmonary hypertensionI27. 0IRCT20200209046427N2Shahid Beheshti University of Medical Sciences100
Completed
Phase 3
DECLARE-TIMI58JPRN-jRCT2080222423AstraZeneca KK17,150